-
Mashup Score: 0
Additional follow-up of the IMspire150 trial showed that overall survival was not significantly improved with atezolizumab, vemurafenib, and cobimetinib compared with placebo, vemurafenib, and cobimetinib in patients with BRAFV600 mutation-positive advanced melanoma. Results of the final analysis are awaited to establish whether a significant improvement in overall survival can be achieved with…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0FDA approves cobimetinib for histiocytic neoplasms - 1 year(s) ago
The FDA granted accelerated approval to cobimetinib for treatment of certain patients of histiocytic neoplasms. The indication applies to use of cobimetinib (Cotellic, Genentech) for adults with histiocytic neoplasms, including Erdheim-Chester disease, Rosai-Dorfman disease and Langerhans cell histiocytosis.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
FDA approves cobimetinib for histiocytic neoplasms. https://t.co/FdfJXfJUcO #cobimetinib @US_FDA #Cotellic @genentech #neoplasms @MSKCancerCenter #HemOnc
-
-
Mashup Score: 5FDA Approves Cobimetinib for Histiocytic Neoplasms - 1 year(s) ago
Based on findings from a phase 2 trial conducted by Memorial Sloan Kettering Cancer Center, the FDA has approved the use of cobimetinib for patients with histiocytic neoplasms.
Source: Targeted OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
FDA Approves #Cobimetinib for #Histiocytic Neoplasms | @TargetedOnc #RDD #ECD #LCH #RareDisease #MEKi https://t.co/f3SpWNUzgA
-
-
Mashup Score: 0
Adding atezolizumab to vemurafenib plus cobimetinib provided promising intracranial activity in patients with BRAFV600-mutated melanoma with CNS metastases.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Also in the September issue: #Atezolizumab, #vemurafenib, and #cobimetinib in patients with #melanoma with #CNS #metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study https://t.co/NgS9ywLTsT
-
-
Mashup Score: 0
Adding atezolizumab to vemurafenib plus cobimetinib provided promising intracranial activity in patients with BRAFV600-mutated melanoma with CNS metastases.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Online first: #Atezolizumab, #vemurafenib, and #cobimetinib in patients with #melanoma with #CNS #metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study https://t.co/NgS9ywLTsT https://t.co/KxW0CKGZq7
-
-
Mashup Score: 0
A patient with stage IV breast cancer perceived multiple green spots in both eyes and had multifocal, hypopigmented, cream-colored spots on the posterior poles on a dilated fundus examination. What would you do next?
Source: jamanetwork.comCategories: OphthalmologyTweet-
Bilateral, multifocal serous detachments in the setting of MEK inhibitor-associated retinopathy (MEKAR) following initiation of #cobimetinib https://t.co/VrCXYKVqk8
-
-
Mashup Score: 0
A patient with stage IV breast cancer perceived multiple green spots in both eyes and had multifocal, hypopigmented, cream-colored spots on the posterior poles on a dilated fundus examination. What would you do next?
Source: jamanetwork.comCategories: OphthalmologyTweet-
Bilateral, multifocal serous detachments in the setting of MEK inhibitor-associated retinopathy (MEKAR) following initiation of #cobimetinib https://t.co/w2RSbbuR5I
-
Online first: Overall #survival with first-line #atezolizumab in combination with #vemurafenib+#cobimetinib in BRAFV600 mutation-positive advanced #melanoma: second interim analysis of IMspire150 https://t.co/8D8ccSYz8B